Pharmacyclics LLC, of Sunnyvale, Calif., an Abbvie company, reported that Imbruvica (ibrutibin) improved progression-free survival, the primary endpoint, as well as multiple secondary endpoints, including overall survival and overall response rate, in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in the final analysis of the phase III RESONATE-2 (PCYC-1115) trial.